Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.

about

Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.

Item

http://www.wikidata.org/entity/Q47283231

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparative study of radiother ...... ensity score-matched analysis.

@en

Comparative study of radiother ...... ensity score-matched analysis.

@nl

type

Item

label

Comparative study of radiother ...... ensity score-matched analysis.

@en

Comparative study of radiother ...... ensity score-matched analysis.

@nl

prefLabel

Comparative study of radiother ...... ensity score-matched analysis.

@en

Comparative study of radiother ...... ensity score-matched analysis.

@nl

P1476

Comparative study of radiother ...... ensity score-matched analysis.

@en

P2093

D Du

http://www.w3.org/2001/XMLSchema#string

M Fang

http://www.w3.org/2001/XMLSchema#string

S Wu

http://www.w3.org/2001/XMLSchema#string

T Song

http://www.w3.org/2001/XMLSchema#string

X Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.

Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.

Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.

Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.

Prognostic impact of the 6th and 7th American Joint Committee on Cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy.

Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.

Cancer statistics in China, 2015.

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/DOTE/DOX060

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28859362

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy